| abstract |
Claimed is the use of ITE (2-(1’H-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester / 2-(1H-indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester / methyl 2-(1H-indol-3-ylcarbonyl)-1,3-thiazole-4-carboxylate) or one of its analogues as represented by the general formula (I) in the manufacture of a medicament for treating a cancer selected from the group consisting of: prostate, liver, lung, ovarian and breast cancer, in a patient in need thereof, wherein the medicament is formulated to deliver to the patient between 1 and 80 mg/kg of the compound; wherein X and Y are independently selected from O or S; R1, R2, R3, R4, RN, R5 and R7, are independently selected from hydrogen or halogen; and R6 is -C(=O)-R10; wherein R10 is selected independently from methoxy, ethyl or methylamino. In particular the most preferred compounds now disclosed include 2-(1H-indol-3-ylcarbonyl)-N-methyl-1,3-thiazole-4-carboxamide / N-methyl-2-(1H-indol-3-ylcarbonyl)-1,3-thiazole-4-carboxamide (abbreviated as ITA) and 1-[2-(1H-indol-3-ylcarbonyl)-1,3-thiazol-4-yl]propan-1-one (ITK). It is suggested that such compounds including 2-(1H-indol-3-ylcarbonyl)-N-methyl-1,3-thiazole-4-carboxamide are provided for the treatment of prostate cancer, liver cancer, lung cancer, ovarian cancer or breast cancer, at a dosing schedule of once or twice daily in an amount between 1 and 10 mg/kg. |